<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110149</url>
  </required_header>
  <id_info>
    <org_study_id>2004P000044</org_study_id>
    <secondary_id>CDR0000409723</secondary_id>
    <secondary_id>NCI-2011-02445</secondary_id>
    <nct_id>NCT00110149</nct_id>
  </id_info>
  <brief_title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of Yttrium-90-Labeled Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as First Line Treatment in Indolent Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others, such as yttrium Y 90&#xD;
      ibritumomab tiuxetan, find cancer cells and help kill them or carry cancer-killing substances&#xD;
      to them without harming normal cells. Giving rituximab together with yttrium Y 90 ibritumomab&#xD;
      tiuxetan may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving rituximab together with yttrium Y 90&#xD;
      ibritumomab tiuxetan works in treating patients with indolent non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine 12-week overall and complete response rate in patients with indolent&#xD;
           non-Hodgkin's lymphoma treated with rituximab and yttrium Y 90 ibritumomab tiuxetan as&#xD;
           first-line treatment.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine 1-year event-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine time to progression and time to next antilymphoma therapy in patients treated&#xD;
           with this regimen.&#xD;
&#xD;
        -  Determine the molecular response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the hematological and non-hematological toxicity of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive rituximab IV followed, no more than 4 hours later, by indium In 111&#xD;
      ibritumomab tiuxetan (for imaging) IV over 10 minutes on day 1. If biodistribution is&#xD;
      acceptable, patients receive rituximab IV followed, no more than 4 hours later, by a single&#xD;
      dose of yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 7, 8, or 9 in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, weeks 6, 10, and 14, every 3 months for 2 years, and&#xD;
      then every 6 months for 2 years.&#xD;
&#xD;
      After completion of study treatment, patients are followed weekly for 3 months, every 3&#xD;
      months for 2 years, and then every 6 months for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-28 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company withdrew drug supply&#xD;
  </why_stopped>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (Complete Response, Unconfirmed Complete Response, and Partial Response) at 12 Weeks</measure>
    <time_frame>14 weeks</time_frame>
    <description>INTERNATIONAL WORKSHOP RESPONSE CRITERIA FOR NON HODGKIN'S LYMPHOMA&#xD;
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non Hodgkin's lymphoma. J Clin Oncol 1999;17(4):1244-53.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EFS</measure>
    <time_frame>1 year</time_frame>
    <description>Event = Death, second malignancy , disease progression.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
    <arm_group_label>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed indolent non-Hodgkin's lymphoma (NHL), including 1 of the&#xD;
             following histologic subtypes:&#xD;
&#xD;
               -  Grade1 or 2 follicular lymphoma&#xD;
&#xD;
               -  Small lymphocytic lymphoma (SLL)&#xD;
&#xD;
               -  Marginal zone B-cell lymphoma&#xD;
&#xD;
          -  CD20-positive disease confirmed by immunohistochemistry or flow cytometry&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  At least 1 lesion measuring ≥ 2.0 cm in a single dimension by CT scan&#xD;
&#xD;
          -  Less than 25% bone marrow involvement with lymphoma by bilateral iliac crest bone&#xD;
             marrow aspiration and biopsy within the past 6 weeks&#xD;
&#xD;
          -  No clinically significant impaired bone marrow reserve as evidenced by any of the&#xD;
             following:&#xD;
&#xD;
               -  Hypocellular marrow, as evidenced by 1 of the following:&#xD;
&#xD;
                    -  ≤ 15% cellularity&#xD;
&#xD;
                    -  Marked reduction in bone marrow precursors&#xD;
&#xD;
               -  Platelet count &lt; 100,000/mm^3&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1,500/mm^3&#xD;
&#xD;
               -  History of failed stem cell collection&#xD;
&#xD;
               -  Prior myeloablative therapy&#xD;
&#xD;
          -  No greater than 5,000/mm^3 circulating tumor cells in peripheral blood&#xD;
&#xD;
          -  Requires antilymphoma therapy, as indicated by any of the following:&#xD;
&#xD;
               -  Systemic symptoms&#xD;
&#xD;
               -  B symptoms&#xD;
&#xD;
               -  Cytopenias&#xD;
&#xD;
               -  Malaise&#xD;
&#xD;
               -  Organ compromise&#xD;
&#xD;
               -  Discomfort&#xD;
&#xD;
               -  Pain&#xD;
&#xD;
               -  Disfigurement&#xD;
&#xD;
               -  Rapidly progressive disease&#xD;
&#xD;
               -  Undue anxiety related to not receiving treatment&#xD;
&#xD;
          -  No transformation to intermediate or high-grade NHL&#xD;
&#xD;
          -  No known brain metastases or CNS involvement by lymphoma NOTE: A new classification&#xD;
             scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of&#xD;
             &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,&#xD;
             &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former&#xD;
             terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  WHO 0-2 OR&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count &lt; 5,000/mm^3 (for patients with SLL )&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No anti-murine antibody reactivity (in patients with prior exposure to murine&#xD;
             antibodies or proteins)&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to yttrium Y 90 ibritumomab tiuxetan&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 1 year after&#xD;
             study treatment&#xD;
&#xD;
          -  No other active malignancy except non-melanoma skin cancer&#xD;
&#xD;
          -  No other serious nonmalignant disease that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior pegfilgrastim&#xD;
&#xD;
          -  More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior external beam radiotherapy to &gt; 25% of active bone marrow (involved field or&#xD;
             regional)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery except diagnostic surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior systemic antilymphoma therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent antilymphoma therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Joyce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Cancer Center at University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401-3498</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <results_first_submitted>April 11, 2017</results_first_submitted>
  <results_first_submitted_qc>October 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 21, 2017</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Robin Joyce</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>12 patients were recruited and signed consent. 3 patient were ineligible and were not treated. The total number treated is nine</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
          <description>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12">total number that signed consent to be screened.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="9">total number of patient that passed screening and received treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
          <description>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (Complete Response, Unconfirmed Complete Response, and Partial Response) at 12 Weeks</title>
        <description>INTERNATIONAL WORKSHOP RESPONSE CRITERIA FOR NON HODGKIN'S LYMPHOMA&#xD;
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non Hodgkin's lymphoma. J Clin Oncol 1999;17(4):1244-53.</description>
        <time_frame>14 weeks</time_frame>
        <population>The trial closed prematurely secondary to the company that produced the agent being sold to another company and the agent not being available to treat the full number of patients in this trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
            <description>patient un treated NHL, who were then treated with the Rituximab and Y-90 Ibritumomab Tiuxetan.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Complete Response, Unconfirmed Complete Response, and Partial Response) at 12 Weeks</title>
          <description>INTERNATIONAL WORKSHOP RESPONSE CRITERIA FOR NON HODGKIN'S LYMPHOMA&#xD;
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non Hodgkin's lymphoma. J Clin Oncol 1999;17(4):1244-53.</description>
          <population>The trial closed prematurely secondary to the company that produced the agent being sold to another company and the agent not being available to treat the full number of patients in this trial.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>As the study was not able to be completed the simple number of patients per outcome is listed.</non_inferiority_desc>
            <other_analysis_desc>The trial was to measure the response rate and EFS of patients but the manufacturer of the investigational agent closed and sold the agent to a new company so the trial was not able to be completed.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EFS</title>
        <description>Event = Death, second malignancy , disease progression.</description>
        <time_frame>1 year</time_frame>
        <population>The study was terminated early</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
            <description>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</description>
          </group>
        </group_list>
        <measure>
          <title>EFS</title>
          <description>Event = Death, second malignancy , disease progression.</description>
          <population>The study was terminated early</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Progression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>alive in remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</title>
          <description>Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <description>grade 3 neutropenia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was stopped abruptly when the makers of the investigational agent sold the company and the agent was not available for a significant period of time. Attempts were made to follow all patients for 12 months after treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robin Joyce, MD</name_or_title>
      <organization>BIDMC</organization>
      <phone>617-667-9920</phone>
      <email>rjoyce@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

